Experimental Psychosis Research and Schizophrenia—Similarities and Dissimilarities in Psychopathology

Chapter
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 36)

Abstract

The aim of experimental psychopathology is to delineate overlapping functional disorders of psychoneurobiologically-defined systems where a set of common symptoms may correspond to a variety of nosological entities. According to the vulnerability model of psychosis, experimental research needs to go beyond categories such as “schizophrenia”. Prospective studies of the effects of psychoactive substances in normal control subjects offer several methodological advantages over routine clinical reviews of schizophrenic patients, especially in terms of standardization. Carefully designed studies utilizing a model psychosis paradigm are a step toward symptom-oriented research. Combining psychological and neurobiological techniques, the experimental psychopathological approach can provide us with a valuable tool for psychiatric research.

Keywords

Experimental psychopathology Hallucinogen induced model psychosis Altered state of consciousness Ego-/self disturbance Key functions of model psychosis Psychotoxic basic syndrome 

References

  1. Arnold OH, Hoff H (1953) Körperschemastörungen bei LSD 25. Wiener Zeitschrift für Nervenheilkunde und deren Grenzgebiete 6:259–274PubMedGoogle Scholar
  2. Becker AM (1949) Zur Psychopathologie der Lysergsäurediäthylamidwirkung. Wiener Zeitschrift für Nervenheilkunde 2:402–440Google Scholar
  3. Benedetti G (1995) Die Bleulersche Tradition der Schizophrenielehre und das Burghölzli als Stätte der Psychotherapie bei Schizophrenen. Schweizer Archiv für Neurologie und Psychiatrie 146:195–199PubMedGoogle Scholar
  4. Beringer K (1927) Der Meskalinrausch: seine Geschichte und Erscheinungsweise. Springer, BerlinCrossRefGoogle Scholar
  5. Bleuler E (1911) Dementia praecox, oder, Gruppe der Schizophrenien. Deuticke, LeipzigGoogle Scholar
  6. Bonnot O, Montalembert Md, Kermarrec S, Botbol M, Walter M, Coulon N (2011) Are impairments of time perception in schizophrenia a neglected phenomenon? J Physiol Paris 105:164–169CrossRefGoogle Scholar
  7. Boor Wd (1956) Pharmakopsychologie und Psychopathologie. Springer, BerlinGoogle Scholar
  8. Bowers MB, Freedman DX (1966) Psychedelic experiences in acute psychoses. Arch Gen Psychiatry 15:240–248CrossRefGoogle Scholar
  9. Braus DF (2002) Wahrnehmen zeitlicher Relationen, neuronale Synchronisation und die Schizophrenien. Fortschritte Der Neurologie, Psychiatrie 70:591–600CrossRefGoogle Scholar
  10. Buckman J (1967) Theoretical aspects of LSD therapy. Int J Social Psychiatry 13(2):126–138.Google Scholar
  11. Callaway E (1992) Psychopharmacology’s need for linking variables. Biol Psychiatry 31:1–3CrossRefGoogle Scholar
  12. Chapman J (1966) The early symptoms of schizophrenia. Br J Psychiatry 112:225–251CrossRefGoogle Scholar
  13. Cohen S (1968) A quarter century of research with LSD. Charles C. Thomas, IllinoisGoogle Scholar
  14. Condrau G (1949) Klinische Erfahrungen an Geisteskranken mit Lysergsäure-Diäthylamid. Acta Psychiatr Scand 24:9–32CrossRefGoogle Scholar
  15. Conrad K (1948) Über differentiale und integrale Gestaltfunktion und den Begriff der Protopathie. Der Nervenarzt 19:315–323 Google Scholar
  16. Conrad K (1958) Die beginnende Schizophrenie: Versuch einer Gestaltanalyse des Wahns: Thieme StuttgartGoogle Scholar
  17. Dittrich A (1996) Ätiologie-unabhängige Strukturen veränderter Wachbewußtseinszustände: Ergebnisse empirischer Untersuchungen über Halluzinogene I. und II. Ordnung, sensorische Deprivation, hypnagoge Zustände, hypnotische Verfahren sowie Reizüberflutung. Stuttgart: VWB-Verlag für Wissen und BildungGoogle Scholar
  18. Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31:80–84CrossRefGoogle Scholar
  19. Döhmann M (1978) Eine empirische Untersuchung zum Schizophreniemodell der Bleuler-Schule. Dissertation, Universität ZürichGoogle Scholar
  20. Dumont GJ, Wezenberg E, Valkenberg M, de Jong CA, Buitelaar JK, van Gerven JM, Verkes RJ (2008) Acute neuropsychological effects of MDMA and ethanol (co-) administration in healthy volunteers. Psychopharmacology 197:465–474CrossRefGoogle Scholar
  21. Freedman B, Chapman LJ (1973) Early subjective experiences in schizophrenic episodes. J Abnorm Psychol 82:46CrossRefGoogle Scholar
  22. Geyer MA, Vollenweider FX (2008) Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 29:445–453CrossRefGoogle Scholar
  23. Gouzoulis-Mayfrank E, Habermeyer E, Hermle L, Steinmeyer Am, Kunert HJ, Sass H (1998) Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study. Eur Psychiatry 13:399–406CrossRefGoogle Scholar
  24. Grof S (1967) Use of LSD in personality diagnostics and therapy of psychogenic disorders. Bobbs-Merrill, New YorkGoogle Scholar
  25. Heimann H (1961) Ausdrucksphänomenologie der Modellpsychosen (Psilocybin). Eur Neurol 141:69–84.CrossRefGoogle Scholar
  26. Hellpach W (1941) Funktionelle Differenzierung der “psychischen Stimulantien”. DMW-Deutsche Medizinische Wochenschrift 67:1358–1361CrossRefGoogle Scholar
  27. Hermle L, Fünfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M (1992a) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 32:976–991CrossRefGoogle Scholar
  28. Hermle L, Oepen G, Spitzer M (1988) Zur Bedeutung der Modellpsychosen. Fortschritte der Neurologie Psychiatrie 56:48–58CrossRefGoogle Scholar
  29. Hermle L, Spitzer M, Borchardt D, Gouzoulis E (1992b) Beziehungen der Modell- bzw. Drogenpsychosen zu schizophrenen Erkrankungen. Fortschr Neurol Psychiatr 60:383–392CrossRefGoogle Scholar
  30. Hoch PH (1957) Remarks on LSD and Mescaline. J Nerv Ment Dis 125:442–443CrossRefGoogle Scholar
  31. Hoffer A, Osmond H (1966) Some psychological consequences of perceptual disorder and schizophrenia. Int J Neuropsychiatry 2:1–19PubMedGoogle Scholar
  32. Hoffer A, Osmond H, Weckowicz T (1967) The hallucinogens. Academic Press, New YorkGoogle Scholar
  33. Hollister LE (1961) Clinical, biochemical and psychologic effects of psilocybin. Arch Int Pharmacodyn Ther 130:42–52PubMedGoogle Scholar
  34. Janzarik W (1959) Dynamische Grundkonstellationen in endogenen Psychosen. Springer, BerlinCrossRefGoogle Scholar
  35. Joel E, Fränkel F (1926) Der Haschisch-Rausch. J Mol Med 5:1707–1709Google Scholar
  36. Kant F (1930) Über Reaktionsformen im Giftrausch. Eur Arch Psychiatry Clin Neurosci 91:694–721Google Scholar
  37. Klee GD (1963) Lysergic acid diethylamide (LSD-25) and ego functions. Arch Gen Psychiatry 8:461CrossRefGoogle Scholar
  38. Klosterkötter J, Albers E, Steinmeyer E, Hensen A (1994) Positive oder negative Symptome. Was ist brauchbarer für die Diagnose Schizophrenie? Der Nervenarzt, 444–453Google Scholar
  39. Knauer A, Maloney WJ (1913) A preliminary note on the psychic action of mescalin, with special reference to the mechanism of visual hallucinations. J Nerv Ment Dis 40:425–436CrossRefGoogle Scholar
  40. Kraehenmann R, Küchenhoff B, Böker H, Schick M (2010) Katatones Dilemma unter Kombinationsbehandlung mit Lithium und Risperidon. Psychiatr Prax 37:306–309CrossRefGoogle Scholar
  41. Kraehenmann R, Vollenweider FX, Seifritz E, Kometer M (2012) Crowding deficits in the visual periphery of schizophrenia patients. PLoS ONE 7:e45884CrossRefGoogle Scholar
  42. Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D’Souza DC, Lipschitz D, Abi-Dargham A, Charney DS (2000) Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 47:137–143CrossRefGoogle Scholar
  43. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455–467CrossRefGoogle Scholar
  44. Langs RJ (1967) Stability of earliest memories under LSD-25 and placebo. J Nerv Ment Dis 144:171–184CrossRefGoogle Scholar
  45. Leuner H (1962) Die experimentelle Psychose. Ihre Psychopharmakologie, Phänomenologie und Dynamik in Beziehung zur Person: Versuch einer konditional-genetischen und funktionalen Psychopathologie der Psychose. Springer, Berlin.Google Scholar
  46. Lewin L (1927) Phantastica. Stilke, BerlinGoogle Scholar
  47. Lienert GA (1959) Changes in the factor structure of intelligence tests produced by d-lysergic acid diethylamide (LSD). Neuro-Psychopharmacol, 461–465 (Elsevier, Amsterdam)Google Scholar
  48. Linton HB, Langs RJ (1962) Subjective reactions to lysergic acid diethylamide (LSD-25): measured by a questionnaire. Arch Gen Psychiatry 6:352–368CrossRefGoogle Scholar
  49. Lohmar D, Brudzinska J (2011) Founding psychoanalysis phenomenologically: phenomenological theory of subjectivity and the psychoanalytic experience. Springer, BerlinGoogle Scholar
  50. Ludwig AM (1966) Altered states of consciousness. Arch Gen Psychiatry 15:225CrossRefGoogle Scholar
  51. Masters R, Houston J (2000) The varieties of psychedelic experience: the classic guide to the effects of LSD on the human psyche. Inner Traditions/Bear & Co, New YorkGoogle Scholar
  52. Mullen P (2008) The mental state and states of mind. Cambridge University Press, CambridgeCrossRefGoogle Scholar
  53. Osmond H (1957) A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci 66:418–434CrossRefGoogle Scholar
  54. Sandison RA (1954) Psychological aspects of the LSD treatment of the neuroses. Br J Psychiatry 100:508–515Google Scholar
  55. Sass LA, Parnas J (2003) Schizophrenia, consciousness, and the self. Schizophr Bull 29:427–444CrossRefGoogle Scholar
  56. Savage C (1955) Variations in ego feeling induced by d-lysergic acid diethylamide (LSD-25). Psychoanal Rev, 1–16.Google Scholar
  57. Savage C, Cholden L (1956) Schizophrenia and the model psychoses. J Clin Exp Psychopathol 17:405PubMedGoogle Scholar
  58. Scharfetter C (1995) The self-experience of schizophrenics: empirical studies of the ego-self in schizophrenia, borderline disorders and depression. Private Publication, ZurichGoogle Scholar
  59. Schneider K (1955) Klinische Psychopathologie. Thieme, StuttgartGoogle Scholar
  60. Schröter-Rosendahl C (1980) Beginnende Schizophrenie und verändertes Wachbewusstsein Gesunder: ein empirischer Vergleich mittels einer Selbstbeurteilungsskala. Dissertation, Universität ZürichGoogle Scholar
  61. Sessa B (2005) Can psychedelics have a role in psychiatry once again? Br J Psychiatry 186:457–458CrossRefGoogle Scholar
  62. Small IF, Small JG, Andersen JM (1966) Clinical characteristics of hallucinations of schizophrenia. Dis Nerv Syst 27:349PubMedGoogle Scholar
  63. Spitzer M (1988) Halluzinationen: ein Beitrag zur allgemeinen und klinischen Psychopathologie. Springer, BerlinCrossRefGoogle Scholar
  64. Stockings GT (1940) A clinical study of the mescaline psychosis, with special reference to the mechanism of the genesis of schizophenic and other psychotic states. Br J Psychiatry 86:29–47Google Scholar
  65. Stoll WA (1947) Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe. Schweizer Archiv für Neurologie, Neurochirurgie und Psychiatrie 60:279Google Scholar
  66. Süllwold L, Huber G (1986) Schizophrene Basisstörungen. Springer, BerlinCrossRefGoogle Scholar
  67. Vollenweider FX (2001) Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci 3:265–279PubMedPubMedCentralGoogle Scholar
  68. Vollenweider FX (2008) Neurobiologie der Halluzinogen-Erfahrung. Hans Huber, Hogrefe AG, BernGoogle Scholar
  69. Vollenweider FX, Gamma A, Liechti M, Huber T (1998a) Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers. Neuropsychopharmacology 19:241–251CrossRefGoogle Scholar
  70. Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56:495–507CrossRefGoogle Scholar
  71. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997a) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [< sup > 18 F] fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7:9–24CrossRefGoogle Scholar
  72. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997b) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357–372CrossRefGoogle Scholar
  73. Vollenweider FX, Maguire RP, Leenders KL, Mathys K, Angst J (1998b) Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Research: Neuroimaging 83:149–162CrossRefGoogle Scholar
  74. Weyl B (1951) Versuch einer psychopathologischen analyse der LSD-Wirkung. Dissertation, Universität FreiburgGoogle Scholar
  75. Winters WD (1975) The continuum of CNS excitatory states and hallucinosis. Hallucinations. Wiley, New York, pp 53–70.Google Scholar
  76. Young BG (1974) A phenomenological comparison of LSD and schizophrenic states. Br J Psychiatry 124:64–74CrossRefGoogle Scholar
  77. Ziolko HU (1966) Persönlichkeitsabhängige Veränderungen in der experimentellen Psychose durch Lysergsäurediäthylamid. Arzneimittelforschung 16:249–251PubMedGoogle Scholar
  78. Zubin J, Spring B (1977) Vulnerability: a new view of schizophrenia. J Abnorm Psychol 86:103CrossRefGoogle Scholar
  79. Zucker K (1930) Versuche mit Meskalin an Halluzinanten. Zeitschrift für die gesamte Neurologie und Psychiatrie 127:108–161CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Christophsbad, Klinik für Psychiatrie und PsychotherapieGöppingenGermany
  2. 2.Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and PsychosomaticsUniversity Hospital for Psychiatry ZurichZurichSwitzerland

Personalised recommendations